Consumer Health Changes ‘At Speed Of Instagram’ Drive J&J’s Decision On Separating Businesses
J&J provided color on plans for standalone consumer health business during a business overview with analysts. Multiple separation pathways are being considered.
You may also be interested in...
Paying down Bausch Health’s debt, incurred during previous management’s expansion-by-acquisition strategy when the firm operated as Valeant, has been a box to check from the start of preparing to separate Bausch + Lomb, says CEO Joseph Papa.
J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.
“As we watch the health care landscape continue to evolve, we think that it's only incumbent upon us to think about what kind of an impact that should have on our portfolio,” says CEO Alex Gorsky. The dependable revenue driver with iconic consumer health brands will be separated from J&J’s Rx drug and medical device division as a standalone, publicly traded company.